Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,007.00GBp
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
6,007.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,935,726
52-wk High
6,432.48
52-wk Low
4,544.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 31.13 33.63
EPS (TTM): 2.34 -- --
ROI: 7.86 15.55 15.02
ROE: 28.47 16.92 16.60

CORRECTED-UPDATE 1-AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

Dec 7 AstraZeneca Plc's immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

Dec 07 2018

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

AstraZeneca Plc's immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

Dec 07 2018

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

Dec 7 AstraZeneca Plc's immunotherapy Imfinzi did not meet the main goals of a late-stage study testing the drug as a treatment for advanced head and neck cancer, the London-listed drugmaker said on Friday.

Dec 07 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Nov 29 2018

Biocartis partners with AstraZeneca on lung cancer diagnostics

Nov 29 Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Nov 29 2018

Key AstraZeneca lung cancer treatment misses study goal

AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

Nov 16 2018

UPDATE 2-Key AstraZeneca lung cancer treatment misses study goal

* Study looked at treatment of most advanced lung cancer (Adds details, share movement)

Nov 16 2018

AstraZeneca's pivotal lung cancer trial fails main goal in late stage trial

Nov 16 AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late stage study, the company said on Friday.

Nov 16 2018

Sobi buys rights to AstraZeneca infant drug for $1.5 billion upfront

LONDON AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion.

Nov 13 2018

UPDATE 1-Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront

* AstraZeneca gets 8 pct stake in Swedish drugmaker (Adds Sobi CEO comment and shares)

Nov 13 2018

Earnings vs. Estimates